ESR1 and breast carcinoma: Using the bc-GenExMiner tool (Jézéquel et al. 2012), we were able to identify MSI-1 as a negative prognostic marker for DFS and DMFS for all breast cancer patients and estrogen receptor-positive breast cancer patients only (p < 0.05 in all cases, Fig. 1).